FindTrial
Sign In

Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523832-38-00
Enrollment
42
Registered
2026-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small for gestational age (SGA) and idiopathic short stature (ISS)

Brief summary

Annualized HV after 12 months of treatment

Interventions

DRUGGENOTROPIN 12 mg powder and solvent for solution for injection.
DRUGNgenla 60 mg solution for injection in pre-filled pen

Sponsors

Schneider Children's Medical Center Of Israel
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Annualized HV after 12 months of treatment—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 25, 2026